Immuno-Reactive Trypsine and extern pancreatic status in cystic fibrosis children  by Chaillou, E. et al.
9. Gastrointestinal and liver disease S79
319* Immuno-Reactive Trypsine and extern pancreatic status in cystic
ﬁbrosis children
E. Chaillou1, A.C. Wagner1, M. Beaumesnil1, C. Bonnemains1, E. Darviot1,
J.L. Ginie`s1. 1Centre de Ressources et de Compe´tences pour la Mucoviscidose,
Centre Hospitalier et Universitaire, Angers, France
Background: The aim of our study was to evaluate the signiﬁcance of the Immuno-
Reactive Trypsine (IRT) as a marker for exocrine pancreatic insufﬁciency, assessed
on fecal elastase, in pancreatic sufﬁcient and insufﬁcient cystic ﬁbrosis (CF)
children.
Patients and Methods: From August 2006 to January 2008, ﬁfty-six children
followed-up in CF Centre, Department of Pediatrics, Angers (France), were studied.
From their fecal elastase concentration they were divided into 2 groups: pancreatic
sufﬁcient or insufﬁcient (>200mg/g of stool or ×100mg/g of stool). For every
patient, IRT concentration was assessed on a dried blood sample.
Results: The ﬁfty pancreatic sufﬁcient patients all had IRT concentrations upper
than 9.5 ng/mL, whatever their age. Thirty-four of the 41 pancreatic insufﬁcient
patients had IRT concentrations lower than 9.5 ng/mL whatever their age, and 33 of
the 35 pancreatic insufﬁcient patients over than 4 years-old had IRT concentrations
lower than 9.5 ng/mL. IRT concentration lower than 9.5 ng/mL measured in a more
than 4 years-old CF child permit to afﬁrm that he has pancreatic insufﬁciency,
with sensibility of 94%, speciﬁcity of 100%, positive predictive value of 100% and
negative predictive value of 83%.
Conclusion: From the age of 4 in cystic ﬁbrosis children, IRT concentration is
correlated with extern pancreatic status. This could be used as a marker for exocrine
pancreatic insufﬁciency when difﬁculties to obtain stools in consultation.
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The inﬂuence of genetic and epigenetic factors on functional status of pancreas
in patients with cystic ﬁbrosis and on course of the disease in general has been
analysed.
96 cases of CF were veriﬁed at Lviv regional CF centre and 89 CF patients were
under observation in terms from 2 month to 12 years. Among them 13 (13.4%)
died − 9 (69.2%) girls and 4 (30.8%) boys. The studied group of patients was
divided on the genotype differences and disease manifestation severity and the
obtained results of glucose-toleration test, sonographical investigation data and
faecal elastase-1 level were compared.
It was determined that CFTR genotype inﬂuences on exocrine pancreatic insufﬁ-
ciency manifestation.”Major” CFTR mutation associates with severe exocrine pan-
creatic insufﬁciency phenotype. “Minor” changes of alleles dominate on “severe”
and could result sufﬁcient exocrine function of pancreas. Both negative (for the
F508del mutation) and positive (for the 3849+10kbC→T, R334W, 3272−11A>G
mutations) correlations between genotype and the degree of exocrine pancreatic
insufﬁciency have been revealed.
CF patient genotype and the degree of exocrine pancreatic insufﬁciency don’t
seem to determine his endocrine status and dynamics of progression of ﬁbrotic
and atrophic changes in pancreas. It is established that older age of cystic ﬁbrosis
patients, progression of ﬁbrotic and atrophic changes in pancreas as well as severe
pulmonary insufﬁciency, all are predictors of deterioration in endocrine function of
pancreas.
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Aims: Meconium ileus (MI) is the presenting symptom in 20% of patients with
cystic ﬁbrosis (CF). The aims of the present study were to assess the clinical
outcomes in cohorts of CF patients with MI at 5, 10 and 15 years in comparison
to patients without MI.
Methods: Clinical records of CF patients with and without MI admitted to a tertiary
referral centre were examined. In patients with MI, data on birth weight, genotype,
type and extent of surgery, duration of parenteral nutrition were recorded. In both
groups clinical status at 5, 10, and 15 years were accessed from annual review
records.
Results: Eighteen patients (7 F) (with MI) and 16 controls (5 F) (without MI)
were reviewed. Of the patients, 8 were homozygous for DF508, 4 were simple
MI and 11 patients received parenteral nutrition for a median of 24 days (10–
120 days). Compared with controls, the median weight, height, FEV1, FVC,
Shwachman score, at 5 years, were 16.9 kg (13.6−23) [20 kg (14.5−27.8)]*, 105 cm
(102–120) [109.8 cm (100.1–121.0)], 82% (36–121) [86% (83−94)], 82% (36–121)
[92% (85–107)]*, and 93 (83–113) [86 (75−92)]; at 10 years were 30.4 kg (25−39)
[32.4 kg (22.9−46.8)], 134 cm (127–140) [138 cm (126–149)], 76% (66−72) [83%
(64–102)]*, 76% (42−98) [93% (83–113)]* and 85 (65−87) [84 (59−94)]; and at
15 years, 52 kg (28−65) [42.6 kg (34.7−59.8)]*, 161 cm (135–170) [156.7 cm (140–
185)], 77% (63–104) [86% (49–119)]*, 80% (77−99) [90% (63–118)]*, and 71
(57−79) [71.5 (62−81].
Abnormal ﬁndings on ultrasound scan (USS) of the liver were seen 36% (45), 70%
(35)*, and 85% (60)* of patients at 5, 10 and 15 years.
*P 0.05.
Conclusion: The study has shown that patients without MI have better growth
and lung function parameters throughout childhood. Abnormal USS of liver is
signiﬁcantly higher in patients with both simple and complicated MI.
322 Intestinal inﬂammation is present in young infants with cystic
ﬁbrosis
A. Lisowska1, J. Walkowiak1,2. 1Department of Gastroenterology & Metabolism,
Poznan University of Medical Sciences, Poznan, Poland; 2Department of Dietetics,
University of Life Sciences, Poznan, Poland
Background: It has been documented that intestinal inﬂammation is one of the
major features of cystic ﬁbrosis (CF). However, the age of its onset is not well
known. Therefore, we have aimed to assess whether intestinal inﬂammation is
present in young CF infants at diagnosis.
Material and Methods: The study comprised 10 infants detected in CF neonatal
screening programme. The age of infants at the assessment was in range from 6
to 10 weeks. Intestinal inﬂammation was assessed by the measurement of fecal
calprotectin concentrations (Immundiagnostik AG, Bensheim, Deutschland). Three
children were pancreatic sufﬁcient at the assessment (fecal elastase-1 concentra-
tions: 200, 350 and 680mcg/g of stool), the remaining seven were pancreatic
insufﬁcient (fecal elastase-1 concentrations from 6 to 33mcg/g of stool).
Results: The range of fecal calprotectin concentrations was from 7.5 to 400mg/L
(median 81.2; mean+SEM: 42.5+37.3). In 8 (80%) infants abnormal calprotectin
results were obtained. The highest value, signiﬁcantly different than in the other
subjects, was observed in an infant who was operated due to meconium ileus.
However, the second child who experienced meconium ileus and was treated in
a conservative mode presented with normal calprotectin concentration (7.5mg/L).
No differences between pancreatic sufﬁcient and insufﬁcient patients were detected.
However, all pancreatic sufﬁcient subjects presented with abnormal calprotectin
results.
Conclusions: Intestinal inﬂammation is already present in young CF infants.
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